Skip to main content
SpringerLink
Log in

Preliminary evidence supports use of rifaximin in hepatic encephalopathy

  • New Drugs and Therapeutics
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hepatic encephalopathy. In: Wilson JD, et al., editors. Harrison’s principles of internal medicine, 12th ed. New York: McGraw-Hill, 1991: 1348–50

  2. Hepatic encephalopathy. In: Sherlock S, et al., editors. Diseases of the liver and biliary system, 9th ed. Oxford: Blackwell Scientific Publications, 1993: 86–101

  3. Gillis JC, Brogden RN. Rifaximin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 1995; 49: 467–84

    Article  PubMed  CAS  Google Scholar 

  4. 1995 Physicians GenRx. St. Louis, Missouri: Mosby-Year Book, Inc. 1995

  5. British National Formulary No. 29. London: The Pharmaceutical Press, 1995; 48–9

  6. De Leo C, Eftimiadi C, Schito GC. Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin. Drugs Exp Clin Res 1986; 12: 979–81

    PubMed  Google Scholar 

  7. Eftimiadi C, De Leo C, Schito GC. Treatment of hepatic encephalopathy with L/105, a new non-absorbable rifamycin. Drugs Exp Clin Res 1984; 10: 691–6

    Google Scholar 

  8. Descombe JJ, Dubourg D, Picard M, et al. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res 1994; 14: 51–6

    PubMed  CAS  Google Scholar 

  9. Verardi S, Verardi V. Bile rifaximin concentration after oral administration in patients undergoing cholecystectomy. Farmaco 1990 Jan; 45: 131–5

    PubMed  CAS  Google Scholar 

  10. Bucci L, Palmieri GC. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin 1993; 13(2): 109–18

    Article  PubMed  CAS  Google Scholar 

  11. Massa P, Vallerino E, Dodero M. Treatment of hepatic encephalopathy with rifaximin: double blind, double dummy study versus lactulose. Eur J Clin Res 1993; 4: 7–18

    Google Scholar 

  12. Fera G, Agostinacchio F, Nigro M, et al. Rifaximin in the treatment of hepatic encephalopathy. Eur J Clin Res 1993; 4: 57–66

    Google Scholar 

  13. Pedretti G, Calzetti C, Missale G, et al. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cir-rhotics. A double-blind, randomized trial. Ital J Gastroenterol 1991 May; 23: 175–8

    PubMed  CAS  Google Scholar 

  14. Di Piazza S, Filippazzo MG, Valenza LM, et al. Rifaximine versus neomycin in the treatment of portosystemic encephalopathy. Ital J Gastroenterol 1991 Sep–Oct; 23: 403–7

    PubMed  Google Scholar 

  15. Fraser CL, Arieff AI. Hepatic encephalopathy. N Engl J Med 1985; 313: 865–73

    Article  PubMed  CAS  Google Scholar 

  16. Crossley IR, Williams R. Progress in the treatment of chronic portasystemic encephalopathy. Gut 1994; 25: 85–98

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Preliminary evidence supports use of rifaximin in hepatic encephalopathy. Drugs Ther. Perspect 5, 5–7 (1995). https://doi.org/10.2165/00042310-199505100-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199505100-00002

Keywords

Search

Navigation